Please Subscribe to get a daily link to Pat's blog via email

Subscribe!

Your privacy is important to us. We will never spam you and keep your personal data secure.

proteasome inhibitor

Home/Tag:proteasome inhibitor
23 09, 2015

Update on ixazomib

Tags: , , , |4 Comments

Don't sleep on ixazomib. My sources tell me to expect a flood of positive data about Takeda's oral proteasome inhibitor (MLN9708) at this year's ASH in Orlando. We should get a glimpse of things to come at the 15th International Myeloma Workshop (IMW 2015) in Rome, Italy, from September 23 to 26, 2015. Ixazomib is

28 02, 2014

BREAKING NEWS: Marizomib granted FDA orphan drug status

Tags: , , |6 Comments

Triphase Accelerator Corp. announced today that it's new proteasome inhibitor, marizomib, has been granted orphan drug designation by the FDA's Office of Orphan Products Development for the treatment of multiple myeloma. Here's a statement about it from the CEO of Tiphase: “We are pleased that the FDA has granted orphan drug designation for the development

19 03, 2013

Responding to IMiD and proteasome inhibitor may be game changer

Tags: , , , , , , , , , , |18 Comments

Friday I left everyone hanging when I wrote:  Monday I am going to explain how this seemingly mundane result–a 0.2 M-spike–may have been the most fateful news I have ever received as a soon to be six year multiple myeloma survivor.  I know I said Monday.  But I couldn't resist yesterday's fun and frivolous, self

12 03, 2013

BREAKING NEWS: HIV drug may help Velcade and Kyprolis work better

Tags: , , , , , , , |5 Comments

  I haven't had a chance to review the data yet, but Danny Parker forwarded me these links moments ago: Pat, This just off the medical press and called out by Dr. Robert Orlowski. Oral protease inhibitor, Nelfinavir, used against HIV, enhances the activity of Bortezomib against myeloma. Even more important, it appears to overcome

12 08, 2012

Millennium Pharmaceutical’s MLN9708 has a name: ixazomib

Tags: , , , |0 Comments

Remember this name: ixazomib (ix az' oh mib) Originally dubbed MLN9708, Millennium Pharmaceutical's experimental proteasome inhibitor has as much potential to help patients as any new anti-myeloma drug in the research pipeline. So don’t you think that it deserved a name? To clarify, this isn’t the new drug’s trade name. Think about Onyx’s new proteasome

23 06, 2012

Exciting new research helps prove timing can be everything!

Tags: , , , , , |2 Comments

Have you read yesterday's post?  Think the timing of when and how you use a drug isn't important?  Check-out this research development which relies on timing to help break-down myeloma cells: Stopping and Starting Cancer Cell Cycle Weakens and Defeats Multiple Myeloma ScienceDaily (June 21, 2012) — Weill Cornell Medical College researchers have devised an

5 02, 2012

Oncology: November 2011 Supplement well worth a look…

Tags: , , , , |0 Comments

Interested in doing a bit of "light reading" this weekend?  Then don't access the following three links I have been saving since November! Maybe you should just file these away for anytime you need a detailed anti-myeloma drug profile: The Future of Treatment for Patients With Relapsed/Refractory Multiple Myeloma Lots of in-depth information here about

25 01, 2012

Helpful summary of new proteasome inhibitor anti-myeloma agents in the research pipeline

Tags: , , , , |0 Comments

Here is a link to an excellent Myeloma Beacon review/summary which compares different experimental proteasome inhibitors Marizomib (NPI-0052) and MLN9708 with Velcade and carfilzomib: Marizomib May Be Effective In Relapsed / Refractory Multiple Myeloma (ASH 2011) Hopefully, each of these three new agents will help a number of patients who have become refractory to Velcade

31 12, 2011

Millennium Pharmaceutical’s year in review

Tags: , , , , |0 Comments

I wanted to share some excerpts from a sort of "year in review" interview with Dr. Deborah Dunsire, CEO of Millennium Pharmaceuticals, makers of Velcade.  I found this article on a site called Mass High Tech.com earlier this month: Millennium reports myeloma drug advances, updates drug recalls By Lori Valigra, Mass High Tech correspondent Cambridge: 

11 09, 2010

Sale Of Carfilzomib Rights In Japan Provides Cash For Continued Research By Onyx Pharmaceuticals

Tags: , , , |2 Comments

I'm getting to this story a few days late, but that doesn't mean it isn't important. Business news does directly affect multiple myeloma patients. This sale provides Onyx Pharmaceuticals, makers of the new proteasome inhibitor carfilzomib, a much needed cash infusion to continue research and fund more clinical studies:Onyx licenses to Ono Japanese rights to

9 09, 2010

Early Research Study Using New Oral Proteasome Inhibitor Shows Promise

Tags: , , , |0 Comments

Velcade is currently the only FDA approved proteasome inhibitor. Here is an encouraging research study using a new oral proteasome inhibitor ONX 0912, which was submitted to the internationally recocognized medical journal, Blood, April 2, 2010; accepted August 8, 2010. Here is a copy of the study abstract:A novel orally active proteasome inhibitor ONX 0912

15 08, 2010

New Phase 2 Study In England Features Kinase Inhibitor, AT7519, For Patients With Relapsed Or Refractory Multiple Myeloma

Tags: , , , , , |2 Comments

The Journal of New England Technology ran this article Friday:MMRC joins UK biotech in start of multiple myeloma trialA Phase 2 clinical trial of a treatment for relapsed or refractory multiple myeloma has launched, led by U.K.-based Astex Therapeutics Ltd. and funded by Norwalk, Conn.-based Multiple Myeloma Research Consortium (MMRC). Noopur Raje, of the Massachusetts

13 06, 2010

Thoughts About My Interview With Onyx Pharmaceuticals’ Chief Medical Officer, Dr. Michael Kauffman At ASCO

Tags: , , , , , , , |0 Comments

I started an article about carfilzomib last Tuesday this way:  The Truth About The New Multiple Myeloma Novel Therapy Drug, Carfilzomib:"Is Onyx Pharmaceuticals' new, next generation proteasome inhibitor a new miracle drug—or just another “bit player” on the multiple myeloma scene? It depends who you ask."Well, you just read my interview with Dr. Michael Kauffman,

12 06, 2010

Interview With Onyx Pharmaceuticals’ CMO Dr. Michael Kauffman- Part Two

Tags: , , , , , , |0 Comments

Yesterday I explained why my interview with Dr. Kauffman was so informal. Using a relaxed, conversational style allows me to get a feel for the moment. More than that, I can try to get a sense of how my subject really feels. Are the guarded? Or they hiding something? Are he or she genuinely enthusiastic

11 06, 2010

Interview With Onyx Pharmaceuticals’ Chief Medical Officer, Michael Kauffman- Part One

Tags: , , , , , |4 Comments

As promised, here is Part One of my three part series about last Friday's interview with Dr. Michael Kauffman, Chief Medical Officer/for Onyx Pharmaceuticals, maker of the new proteasome inhibitor, carfilzomib.First, here is what Google has to say about Dr. Kauffman:Director, CombinatoRx, Inc. CMO, Onyx PharmaceuticalsBoston , MA Sector: HEALTHCARE / Biotechnology 46 Years Old

8 06, 2010

The Truth About The New Multiple Myeloma Novel Therapy Drug, Carfilzomib

Tags: , , , , |3 Comments

Is Onyx Pharmaceuticals' new, next generation proteasome inhibitor a new miracle drug—or just another “bit player” on the multiple myeloma scene? It depends who you ask.The company is pushing comparisons with the only currently available FDA proteasome inhibitor, Velcade. Company officials point to ongoing research study results which show less risk of developing peripheral neuropathy

5 06, 2010

Follow-Up Analysis Of Onyx Pharmaceuticals’ Carfilzomib 004 Study Against Refractory Multiple Myeloma

Tags: , , , |1 Comment

Onyx Pharmaceuticals' Carfilzomib Highlights First Day Of ASCO Meetings In ChicagoFlaunting an impressive 55% success rate in previously treated multiple myeloma patients, Onyx Pharmaceuticals revealed the results of their ongoing Phase 2 clinical carfilzomib study, 004 at the American Society of Clinical Oncology (ASCO) meetings here in Chicago.Carfilzomib is a selective, next-generation proteasome inhibitor, similar

25 05, 2010

Clarification About New Oral Proteasome Inhibitor–MLN9708 From Millennium

Tags: , , , , , |6 Comments

Sunday, I ran a story about Millennium Pharmaceutical's upcoming research presentations at ASCO. At the end of the article, I commented about the lack of attention being paid to Millennium's development of an "oral Velcade," a new drug, MLN9708.For years, the myeloma community has heard rumors Millennium was close to unveiling such a drug.  Now, practically

23 05, 2010

MILLENNIUM ANNOUNCES VELCADE PRESENTATIONS AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING

Tags: , , , , , , |1 Comment

I learned yesterday VELCADE is being highlighted in five presentations at the newly established, exclusive Trials in Progress session. This session will highlight a number of different abstracts. “Data being presented at this year’s ASCO further demonstrate the effectiveness of VELCADE as a backbone of therapy in a range of multiple myeloma patient populations and